NanoString Technologies, Inc. (NASDAQ:NSTG) updated its FY17 earnings guidance on Thursday. The company provided EPS guidance of ($1.99-1.86) for the period, compared to the Thomson Reuters consensus EPS estimate of ($2.10). The company issued revenue guidance of $109-112 million, compared to the consensus revenue estimate of $110.55 million.

Several analysts have recently commented on the company. Cowen and Company reissued a buy rating and issued a $20.00 price objective on shares of NanoString Technologies in a research note on Thursday, September 28th. ValuEngine downgraded NanoString Technologies from a hold rating to a sell rating in a research note on Thursday, July 13th. BidaskClub downgraded NanoString Technologies from a hold rating to a sell rating in a research note on Sunday, July 16th. Zacks Investment Research raised NanoString Technologies from a sell rating to a hold rating in a research note on Tuesday, July 25th. Finally, Janney Montgomery Scott downgraded NanoString Technologies from a buy rating to a neutral rating in a research note on Thursday, October 12th. Three analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $17.25.

NanoString Technologies, Inc. (NSTG) traded down $1.99 during mid-day trading on Friday, hitting $7.79. The stock had a trading volume of 1,260,000 shares, compared to its average volume of 277,696. The company has a debt-to-equity ratio of 0.93, a current ratio of 4.22 and a quick ratio of 3.74. NanoString Technologies, Inc. has a 52 week low of $7.32 and a 52 week high of $23.45.

NanoString Technologies (NASDAQ:NSTG) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.11. The company had revenue of $27.02 million during the quarter, compared to analyst estimates of $26.27 million. NanoString Technologies had a negative return on equity of 227.21% and a negative net margin of 44.24%. NanoString Technologies’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.51) earnings per share. analysts anticipate that NanoString Technologies, Inc. will post -2.26 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at

NanoString Technologies Company Profile

NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

Receive News & Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.